Biomarker may predict immunotherapy response in liver cancer
October 18, 2024
October 18, 2024
ITHACA, New York, Oct. 18 -- Cornell University issued the following news:
It may soon be possible to determine which patients with a type of liver cancer called hepatocellular carcinoma would benefit from immunotherapy, according to a preclinical study by Weill Cornell Medicine investigators.
The study, published Oct. 17 in Molecular Cell, provides new insights into a pair of proteins, p62 and NBR1, and their opposing functions in regulating the interferon response in . . .
It may soon be possible to determine which patients with a type of liver cancer called hepatocellular carcinoma would benefit from immunotherapy, according to a preclinical study by Weill Cornell Medicine investigators.
The study, published Oct. 17 in Molecular Cell, provides new insights into a pair of proteins, p62 and NBR1, and their opposing functions in regulating the interferon response in . . .